Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Efficacy and Safety of rAHF-PFM in Pediatric Hemophilia A
NCT00157040Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2002
- Primary completion
- Jan 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Takeda. Primary endpoint: Terminal phase half-life of Recombinant Antihemophilic Factor (rAHF-PFM) at 48 hours. Started Jun 2002; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00157040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157040.